| Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis L Tanneau, EM Svensson, S Rossenu, MO Karlsson CPT: Pharmacometrics & Systems Pharmacology 10 (12), 1538-1549, 2021 | 27 | 2021 |
| Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis L Tanneau, MO Karlsson, EM Svensson British journal of clinical pharmacology 86 (5), 913-922, 2020 | 16 | 2020 |
| Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens L Tanneau, MO Karlsson, SL Rosenkranz, YS Cramer, J Shenje, ... Clinical Pharmacology & Therapeutics 112 (4), 873-881, 2022 | 12 | 2022 |
| Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline L Tanneau, MO Karlsson, AH Diacon, J Shenje, J De Los Rios, L Wiesner, ... Clinical Pharmacokinetics, 1-9, 2022 | 8 | 2022 |
| Model-predicted impact of ECG monitoring strategies during bedaquiline treatment SW van Beek, L Tanneau, G Meintjes, S Wasserman, NR Gandhi, ... Open forum infectious diseases 9 (8), ofac372, 2022 | 3 | 2022 |
| Model-Based Characterization of the Bidirectional Interaction between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with … AM Grisic, W Xiong, L Tanneau, S Jönsson, LE Friberg, MO Karlsson, ... Clinical Cancer Research, 2021 | 2 | 2021 |
